6:00 PM
 | 
Oct 04, 2012
 |  BC Extra  |  Top Story

Teva: no trial yet for biosimilar rituximab

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) told BioCentury it has yet to begin a Phase III trial of its biosimilar version of autoimmune and cancer drug MabThera rituximab, citing "changes in the regulatory and competitive environment." According to the EU Clinical Trials Register, a planned ex-U.S. Phase III trial comparing the biosimilar to...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >